RxDoctor Payments Data

Nasar Katariwala, MD

Neurology · Michigan City, INNPI 1356311310

Payments from drug & device makers

$14,758in general payments, 2019–2025

Across 677 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • AbbVie$910
  • Teva Pharmaceuticals USA, Inc.$540
  • SK Life Science, Inc.$536
  • EMD Serono, Inc.$515
  • UCB, Inc.$494
  • plus $8K from 52 others

What the payments were for

  • Speaking & faculty fees$650%
  • Food & beverage$11,92881%
  • Education$961%
  • Gifts$2,67018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis101$4,199
AbbVie(2 entities)85$910
Teva Pharmaceuticals USA, Inc.28$540
SK Life Science, Inc.26$536
EMD Serono, Inc.33$515
UCB, Inc.24$494
Lilly USA, LLC23$476
Biogen24$459
Johnson & Johnson19$416
Sunovion Pharmaceuticals Inc.24$357
Sanofi17$357
Neurocrine Biosciences, Inc.15$351
Lundbeck LLC15$328
Argenx US, Inc.13$262
Impel Pharmaceuticals Inc.13$257
Amgen12$252
Amneal Pharmaceuticals LLC13$247
Eisai Inc.11$245
Upsher-smith Laboratories LLC12$239
Acadia Pharmaceuticals Inc14$224
Livanova USA, Inc.12$220
Pfizer12$218
MDD US Operations, LLC11$206
Harmony Biosciences LLC6$181
Supernus Pharmaceuticals, Inc.9$173
TG Therapeutics, Inc.6$170
Kyowa Kirin, Inc.7$143
Abbott7$128
Adamas Pharmaceuticals, Inc.7$123
Neurelis, Inc.5$115
Avanir Pharmaceuticals, Inc.6$112
Banner Life Sciences, LLC5$108
Mallinckrodt Hospital Products Inc.5$108
AstraZeneca(2 entities)5$98
Catalyst Pharmaceuticals, Inc.5$95
Genentech USA, Inc.4$94
Biohaven Pharmaceuticals, Inc.6$75
ANI Pharmaceuticals, Inc.2$69
Vanda Pharmaceuticals Inc.2$67
Acorda Therapeutics, Inc3$65
Otsuka America Pharmaceutical, Inc.3$54
Arbor Pharmaceuticals, Inc.4$51
Biohaven Pharmaceutical Holding Company Ltd.3$48
Assertio Therapeutics, Inc.3$46
Sumitomo Pharma America, Inc.2$44
Impel Pharmaceuticals LLC2$39
Octapharma USA, Inc.1$28
Boston Scientific2$26
Avadel CNS Pharmaceuticals, LLC1$26
Aucta Pharmaceuticals, Inc.1$25
Alnylam Pharmaceuticals Inc.1$22
Zyla Life Sciences, Inc.1$22
Bristol Myers Squibb1$20
Corium, LLC1$18
Cycle Pharmaceuticals Inc1$18
Tanabe Pharma America, Inc.1$16
Vertical Pharmaceuticals, LLC1$15
Ceribell, Inc.1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,758 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$268,685
Medicare patients
708
Services billed
2,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate27$228,676
VumerityDiroximel Fumarate13$130,258
NeuproRotigotine43$55,972
BotoxOnabotulinumtoxina27$39,666
UbrelvyUbrogepant23$32,567
RytaryCarbidopa/Levodopa13$30,744
Nurtec OdtRimegepant Sulfate13$18,188
AptiomEslicarbazepine Acetate12$17,659
FycompaPerampanel12$14,082
Lacosamide79$10,121
Lamotrigine ErLamotrigine12$9,759
Carbamazepine ErCarbamazepine71$8,114
Levetiracetam260$6,627
Memantine Hcl ErMemantine Hcl53$5,011
Topiramate ErTopiramate14$5,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$351$228,67627 claims
BiogenVumerity$459$130,25813 claims
AbbVieBotox, Ubrelvy$910$72,23350 claims
UCB, Inc.Neupro$494$55,97243 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$247$32,90564 claims
PfizerNurtec Odt$218$18,18813 claims
Sunovion Pharmaceuticals Inc.Aptiom$357$17,65912 claims
Eisai Inc.Fycompa$245$14,08212 claims
Upsher-smith Laboratories LLCTopiramate$239$1,138120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →